FBRX
Forte Biosciences, Inc.
Healthcare — Biotechnology
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Strong Buy
1.0 / 5
4 analysts
$76.99
(0.00%)
Target:
$63.75
(-17.2%)
Price History
52-Week Range
Sign in to add FBRX to a watchlist or set price alerts.
Fundamentals
| Market Cap | $436.61M |
| P/E Ratio (TTM) | - |
| Forward P/E | -5.15 |
| EPS (TTM) | $-4.58 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -188.40% |
| Debt/Equity | - |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $63.75 |
| Analysts | 4 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 83.6 |
| Beta | 2.87 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $35.80 |
| 52-Week Low | $9.10 |
| 50-Day Avg | $21.98 |
| 200-Day Avg | $22.68 |
| Avg Volume | $1.51M |
| Volume | $1.40M |
Performance Analysis
NEUTRALFBRX presents a mixed picture with both positive and negative indicators.
-
Trading near its 52-week high ($35.80), which may indicate limited upside.
-
RSI at 83.6 indicates overbought conditions — a pullback may be due.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
Wall Street consensus is "Strong Buy" from 4 analysts.
-
Average analyst target of $63.75 implies 17.2% downside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:09 UTC
Back to Screener Export Report